Frisco, Texas, December 8, 2015 – OxySure Therapeutics, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology and other innovative medical solutions, today launched OxyTracTM, a cloud based software system that allows customers to track all their Automated External Defibrillators (AEDs), OxySure units, and other device maintenance, renewals and incidents.
The OxyTrac system provides customers with critical data before, during and after emergency events by tracking critical data such as the expiry dates of AED batteries, AED pads, and OxySure cartridges, as well as inspection data, location information and incident reporting. The system is simple to use yet feature rich, and automatically generates email reminders and notifications of upcoming expiry dates and critical events.
OxyTrac helps customers stay legally compliant and always ready to respond, by providing information that indicates whether AEDs, OxySure units, and other devices are ready when needed. It does so by:
• Locating all AEDs, OxySure units, and other devices on the customer’s premises, ensuring quick access during emergency situations;
• Storing an easy-reference personnel database, with up-to-date contact information to provide back-up help when it is needed;
• Providing all part numbers for easy ordering and maintenance;
• Notifying relevant personnel, in advance, regarding expiration dates of all parts to make sure AED, OxySure, and other devices are always 100% functional and legal;
• Sending regular email reminders, to key personnel, for all required AED, OxySure, and other device inspections; and
• Sending reminders to all relevant personnel regarding CPR Training renewals, as required by law.
OxyTrac also enables customers to document crucial data during an emergency event. It provides a convenient data logging feature to quickly and easily document AED, OxySure, and other device-related incidents. It also includes a security login function to ensure that only authorized personnel have access to AED, OxySure, and other important device data.
As customers may be required to provide accurate accounts of device events, especially with regard to AEDs to comply with Good Samaritan Laws and the CASA Act, OxyTrac provides a comprehensive event-reporting feature that also allows for seamless transfer of data to other digital mediums.
“We are excited about OxyTrac and the way it will make our customers’ lives easier by consolidating the tracking, inspections, maintenance, and monitoring of all their emergency medical devices on one single platform,” said Julian Ross, CEO of OxySure. “We are able to track any device with an expiry date on it, and OxyTrac can provide the confidence of knowing the filing, registration, and submission of the required compliance paperwork has been documented properly.”
OxyTrac pricing is based on a per-device basis, and generally starts at $75 per year for a single AED and $25 per year for a single OxySure unit. Multi-year discounts are provided, and in addition, discounts increase as the number of units being tracked increases. The Company also provides bundling discounts, such as for example pricing for an AED/OxySure combination system.
Launch Discount: The Company also announced that for a limited time customers who sign up for OxyTrac will enjoy an additional 25% discount on OxyTrac pricing on all devices. For a quote customers are invited to call 1-888-7OXYSURE (1-888-769-9787) or email firstname.lastname@example.org.
The OxyTrac system can be accessed by clicking on the Product Catalog menu at the Company’s website located at www.oxysure.com, or directly at http://www.oxysure.com/aed/index.php/oxytrac-device-tracking-system
OxyTrac is powered by TrackPro, an industry leading platform for device tracking. The Company entered into a license agreement to create OxyTrac, a private label, customized, “one stop” solution for OxySure customers to track and manage all their emergency medical devices.
About OxySure Therapeutics, Inc.
OxySure Therapeutics, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products. www.OxySure.com
Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management’s control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Therapeutics, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Therapeutics, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Therapeutics, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2014.
Renmark Financial Communications, Inc.
Bettina Filippone: email@example.com
Tel.: (416) 644-2020 or (514) 939-3989
Redchip Companies, Inc.
Jon Cunningham: firstname.lastname@example.org
Tel.: 800-733-2447, ext. 107